Jürgen Furkert1, Martin Zeier, Vedat Schwenger. 1. Nephrology and Gastroenterology, SLK-Kliniken Heilbronn, Bad Friedrichshall, Germany. juergen.furkert@slk-kliniken.de
Abstract
BACKGROUND: Peritoneal dialysis (PD) solutions sterilized at a low pH level contain only minimal amounts of glucose degradation products (GDPs). The latter are known to have an adverse effect on the peritoneal membrane. The present study retrospectively analyzes the effects on the incidences of peritonitis and exit-site infections. MATERIALS AND METHODS: Data concerning the frequency of peritonitis and exit-site infections for 120 patients treated with PD were collected. Before 2000, 67 of these patients received conventional dialysates and from 2000 on, 53 patients were treated with the new dialysis fluids. Furthermore, a correlation between the incidence of infections and the duration of treatment with dialysis was established. RESULTS: It was observed that the use of dialysis solutions low in GDPs resulted in significantly lower rates of peritonitis (p = 0.002) and exit-site infections (p = 0.02). When using the new treatment, peritonitis occurred, on average, after 48 months of treatment and exit-site infections after 34 months of treatment. DISCUSSION: The result supports the hypothesis that the use of the new, biocompatible, PD solutions contributes to considerable reduction in the rates of peritonitis and exit-site infections. As it is not expected that randomized prospective studies will be conducted in the future, further observational studies should be carried out in order to affirm the observed tendencies.
BACKGROUND: Peritoneal dialysis (PD) solutions sterilized at a low pH level contain only minimal amounts of glucose degradation products (GDPs). The latter are known to have an adverse effect on the peritoneal membrane. The present study retrospectively analyzes the effects on the incidences of peritonitis and exit-site infections. MATERIALS AND METHODS: Data concerning the frequency of peritonitis and exit-site infections for 120 patients treated with PD were collected. Before 2000, 67 of these patients received conventional dialysates and from 2000 on, 53 patients were treated with the new dialysis fluids. Furthermore, a correlation between the incidence of infections and the duration of treatment with dialysis was established. RESULTS: It was observed that the use of dialysis solutions low in GDPs resulted in significantly lower rates of peritonitis (p = 0.002) and exit-site infections (p = 0.02). When using the new treatment, peritonitis occurred, on average, after 48 months of treatment and exit-site infections after 34 months of treatment. DISCUSSION: The result supports the hypothesis that the use of the new, biocompatible, PD solutions contributes to considerable reduction in the rates of peritonitis and exit-site infections. As it is not expected that randomized prospective studies will be conducted in the future, further observational studies should be carried out in order to affirm the observed tendencies.
Authors: David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael Suranyi; Seng H Tan; David Voss Journal: J Am Soc Nephrol Date: 2012-03-22 Impact factor: 10.121
Authors: David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss Journal: Perit Dial Int Date: 2012 Sep-Oct Impact factor: 1.756
Authors: Clara Santos; Miguel Pérez-Fontán; Ana Rodríguez-Carmona; María Calvo-Rodríguez; Andrés López-Muñiz; Beatriz López-Calviño; Teresa García-Falcón Journal: Perit Dial Int Date: 2014-10-07 Impact factor: 1.756
Authors: Claus Peter Schmitt; Barbara Nau; Gita Gemulla; Klaus E Bonzel; Tuula Hölttä; Sara Testa; Michel Fischbach; Ulrike John; Markus J Kemper; Anja Sander; Klaus Arbeiter; Franz Schaefer Journal: Clin J Am Soc Nephrol Date: 2012-11-02 Impact factor: 8.237
Authors: Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kym M Bannister; Philip A Clayton; David W Johnson Journal: Clin J Am Soc Nephrol Date: 2013-08-15 Impact factor: 8.237